APM
EW icon

Avidity Partners Management’s Edwards Lifesciences EW Stock Holding History

Avidity Partners Management’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-440,000
Closed -$51.8M – 88
2022
Q1 		$51.8M Buy
+440,000
New +$49.4M 1.08% 32
2020
Q1 		– Sell
-81,000
Closed -$6.3M – 56
2019
Q4 		$6.3M Buy
+81,000
New +$6.32M 3.97% 8

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Avidity Partners Management's EW Position: Q2 2022 in Review

Avidity Partners Management sold out of Edwards Lifesciences (EW) in Q2 2022, closing a stake of 440,000 shares — an estimated $51.8M sold.

Avidity Partners Management first reported a position in EW in Q4 2019 and held it in 2 quarters. The position peaked at $51.8M in Q1 2022. 1,272 funds tracked by Wall St. Rank hold EW as of Q2 2022.

  • Avidity Partners Management reported no remaining Edwards Lifesciences position as of Q2 2022 after selling out during the quarter.
  • Avidity Partners Management sold 440,000 Edwards Lifesciences shares in Q2 2022, an estimated $51.8M.
  • Avidity Partners Management first reported a position in Edwards Lifesciences in Q4 2019 and held it in 2 quarters.
  • Avidity Partners Management's Edwards Lifesciences position peaked at $51.8M in Q1 2022.
  • 1,272 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2022.

Based on Avidity Partners Management's 13F filing for Q2 2022, filed 15 Aug 2022.